Mesoblast Ltd (MESO) Stock AnalysisMESOMesoblast Ltd

Mesoblast Limited is an Australia-based biotechnology company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company's Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: Chronic heart failure (CHF) and Chronic low back pain (CLBP) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).

Given the current price of $12.28 and a forward P/E ratio of 454.55, the stock appears overvalued at this time despite significant revenue growth. The RSI is at 31.42, indicating that the stock is oversold, but with a 5-day change of -7.53%, it may still face short-term downward pressure. The main risk is the high forward P/E ratio, suggesting that investors are pricing in substantial future growth that may not materialize.

6 analysts cover MESO: 4 rate it Buy, 2 Hold and 0 Sell. The average price target is 35.00.